Comprehensive NeuroScience Announces New Company Name
Comprehensive NeuroScience
is pleased to announce its plans to roll out the new company name,
Comprehensive Clinical Development
. Under its new name, Comprehensive Clinical Development will continue to deliver CRO services in partnership with quality sponsors.
Comprehensive Clinical Development offers full-service capabilities and therapeutic expertise in numerous indications, including, but not limited to, CNS, dermatology, diabetes, infectious disease, obesity, and postmenopausal women, and collects early efficacy data across these populations.
Offering CRO services both of developmental and clinical conduct, Comprehensive Clinical Development leverages the diversity of its service networks to provide biopharmaceutical clients with exceptional quality and cost-effective trial management. Along with early and late phase site clinical conduct, Comprehensive Clinical Development provides a full range of services from protocol writing through final clinical study reporting.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
